BofA lowered the firm’s price target on Alnylam (ALNY) to $462 from $529 and keeps a Buy rating on the shares as part of the firm’s Q4 small-to-mid cap biotech earnings preview.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY: